Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies.

Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Zhu L.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov 10. doi: 10.1002/psp4.12476. [Epub ahead of print]

2.

Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors.

Sanghavi K, Zhang J, Zhao X, Feng Y, Statkevich P, Sheng J, Roy A, Vezina HE.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov 10. doi: 10.1002/psp4.12477. [Epub ahead of print]

3.

Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance.

Hamuro L, Statkevich P, Bello A, Roy A, Bajaj G.

Clin Pharmacol Ther. 2019 Nov;106(5):1018-1027. doi: 10.1002/cpt.1502. Epub 2019 Jul 10.

PMID:
31090921
4.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.

Mita MM, Mita AC, Moseley JL, Poon J, Small KA, Jou YM, Kirschmeier P, Zhang D, Zhu Y, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig SJ, Bannerji R, Shapiro GI.

Br J Cancer. 2017 Oct 24;117(9):1258-1268. doi: 10.1038/bjc.2017.288. Epub 2017 Aug 31.

5.

Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.

Bajaj G, Gupta M, Feng Y, Statkevich P, Roy A.

J Clin Pharmacol. 2017 Dec;57(12):1527-1533. doi: 10.1002/jcph.962. Epub 2017 Aug 11. No abstract available.

6.

No Pharmacokinetic Drug-Drug Interaction Between Prasugrel and Vorapaxar Following Multiple-Dose Administration in Healthy Volunteers.

Anderson MS, Kosoglou T, Statkevich P, Li J, Rotonda J, Meehan AG, Cutler DL.

Clin Pharmacol Drug Dev. 2018 Feb;7(2):143-150. doi: 10.1002/cpdd.354. Epub 2017 Apr 12.

7.

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.

Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, Park JS, Waxman IM, Roy A, Gupta M.

J Clin Pharmacol. 2017 Mar;57(3):394-400. doi: 10.1002/jcph.818. Epub 2016 Sep 27.

PMID:
27557786
8.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone.

Kosoglou T, Kumar B, Statkevich P, Schiller JE, Kantesaria B, Hanson ME, Sisk CM, Cutler DL.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):56-62. doi: 10.1002/cpdd.133. Epub 2014 Sep 28.

PMID:
27128003
9.

Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects.

Chen X, Kosoglou T, Statkevich P, Kumar B, Li J, Dockendorf MF, Wang G, Lowe RS, Jiang J, Liu H, Wang Z, Cutler DL, Hu P.

Int J Clin Pharmacol Ther. 2014 Oct;52(10):889-99. doi: 10.5414/CP202121.

PMID:
25138682
10.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CL.

Clin Breast Cancer. 2014 Jun;14(3):169-76. doi: 10.1016/j.clbc.2013.10.016. Epub 2013 Oct 26.

PMID:
24393852
11.

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ.

Lung Cancer. 2014 Feb;83(2):219-23. doi: 10.1016/j.lungcan.2013.11.020. Epub 2013 Dec 2.

PMID:
24388167
12.

Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial.

Kosoglou T, Hunt TL, Xuan F, Kumar B, Statkevich P, Hanson ME, Cutler DL.

Clin Pharmacol Drug Dev. 2014 Jan;3(1):18-24. doi: 10.1002/cpdd.49. Epub 2013 Sep 25.

PMID:
27128226
13.

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

Nemunaitis JJ, Small KA, Kirschmeier P, Zhang D, Zhu Y, Jou YM, Statkevich P, Yao SL, Bannerji R.

J Transl Med. 2013 Oct 16;11:259. doi: 10.1186/1479-5876-11-259.

14.

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects.

Behm MO, Kosoglou T, Miltenburg AM, Li J, Statkevich P, Johnson-Levonas AO, Martinho M, Fackler P.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):310-5. doi: 10.1002/cpdd.38.

PMID:
27121935
15.

The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.

Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL.

J Clin Pharmacol. 2013 May;53(5):540-9. doi: 10.1002/jcph.20. Epub 2013 Feb 20.

PMID:
23426761
16.

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin.

Kosoglou T, Zhu Y, Statkevich P, Xuan F, Schiller JE, Johnson-Levonas AO, Cutler DL.

Clin Pharmacol Drug Dev. 2013 Jan;2(1):90-8. doi: 10.1002/cpdd.11. Epub 2013 Feb 26.

PMID:
27121563
17.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.

Zhang D, Mita M, Shapiro GI, Poon J, Small K, Tzontcheva A, Kantesaria B, Zhu Y, Bannerji R, Statkevich P.

Cancer Chemother Pharmacol. 2012 Dec;70(6):891-8. doi: 10.1007/s00280-012-1967-y. Epub 2012 Oct 9.

PMID:
23053255
18.

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.

Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riley S, Ploski C, Correia A, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16666-71. doi: 10.1073/pnas.1202529109. Epub 2012 Sep 24.

19.

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.

Statkevich P, Kosoglou T, Preston RA, Kumar B, Xuan F, Trusley C, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1501-8. doi: 10.1007/s00228-012-1269-7. Epub 2012 Apr 19.

PMID:
22527342
20.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL.

Eur J Clin Pharmacol. 2012 Nov;68(11):1509-16. doi: 10.1007/s00228-012-1271-0. Epub 2012 Apr 5.

PMID:
22476387
21.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.

PMID:
22315147
22.

A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

Wong NS, Meadows KL, Rosen LS, Adjei AA, Kaufmann SH, Morse MA, Petros WP, Zhu Y, Statkevich P, Cutler DL, Meyers ML, Hurwitz HI.

Cancer Invest. 2011 Nov;29(9):617-25. doi: 10.3109/07357907.2011.621912.

23.

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.

Kosoglou T, Zhu Y, Statkevich P, Triantafyllou I, Taggart W, Xuan F, Kim KT, Cutler DL.

Eur J Clin Pharmacol. 2011 May;67(5):483-92. doi: 10.1007/s00228-010-0955-6. Epub 2010 Dec 1.

PMID:
21120461
24.

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.

Castaneda C, Meadows KL, Truax R, Morse MA, Kaufmann SH, Petros WP, Zhu Y, Statkevich P, Cutler DL, Hurwitz HI.

Cancer Chemother Pharmacol. 2011 Feb;67(2):455-63. doi: 10.1007/s00280-010-1488-5. Epub 2010 Oct 24.

PMID:
20972873
25.

Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

AbuTarif MA, Krishna G, Statkevich P.

Curr Med Res Opin. 2010 Feb;26(2):397-405. doi: 10.1185/03007990903485056.

PMID:
20001450
26.

Evaluation of the exposure equivalence of oral versus intravenous temozolomide.

Diez BD, Statkevich P, Zhu Y, Abutarif MA, Xuan F, Kantesaria B, Cutler D, Cantillon M, Schwarz M, Pallotta MG, Ottaviano FH.

Cancer Chemother Pharmacol. 2010 Mar;65(4):727-34. doi: 10.1007/s00280-009-1078-6. Epub 2009 Jul 30.

27.

On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, Guilhot F, Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, List A.

Leukemia. 2008 Sep;22(9):1707-11. doi: 10.1038/leu.2008.156. Epub 2008 Jun 12.

PMID:
18548095
28.

Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

Zhu Y, Statkevich P, Cutler DL.

Int J Clin Pharmacol Ther. 2007 Oct;45(10):539-47.

PMID:
17966839
29.

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE.

J Clin Oncol. 2007 Jul 20;25(21):3137-43.

PMID:
17634493
30.

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.

Cortes J, Jabbour E, Daley GQ, O'Brien S, Verstovsek S, Ferrajoli A, Koller C, Zhu Y, Statkevich P, Kantarjian H.

Cancer. 2007 Sep 15;110(6):1295-302.

31.

Disposition of desloratadine in healthy volunteers.

Ramanathan R, Reyderman L, Su AD, Alvarez N, Chowdhury SK, Alton KB, Wirth MA, Clement RP, Statkevich P, Patrick JE.

Xenobiotica. 2007 Jul;37(7):770-87.

PMID:
17620222
32.

Disposition of loratadine in healthy volunteers.

Ramanathan R, Reyderman L, Kulmatycki K, Su AD, Alvarez N, Chowdhury SK, Alton KB, Wirth MA, Clement RP, Statkevich P, Patrick JE.

Xenobiotica. 2007 Jul;37(7):753-69.

PMID:
17620221
33.

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):576-83.

34.

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

Migoya EM, Bergman A, Hreniuk D, Matthews N, Yi B, Roadcap B, Valesky R, Liu L, Riffel K, Groff M, Zhao JJ, Musson DG, Gambale J, Kosoglou T, Statkevich P, Lasseter KC, Laurent A, Johnson-Levonas AO, Murphy G, Gottesdiener K, Paolini JF.

Int J Clin Pharmacol Ther. 2006 Feb;44(2):83-92.

PMID:
16502768
35.

Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients.

Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Maxwell SE, Kosoglou T, Murphy G, Gottesdiener K, Robson R, Paolini JF.

J Clin Pharmacol. 2006 Mar;46(3):328-36.

PMID:
16490809
36.

Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.

Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF.

J Clin Pharmacol. 2006 Mar;46(3):321-7.

PMID:
16490808
37.

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.

Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P.

Curr Med Res Opin. 2005 Aug;21(8):1171-9.

PMID:
16083526
38.

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.

Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR.

Cancer. 2005 Aug 1;104(3):561-9.

39.

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.

Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB.

Clin Pharmacokinet. 2005;44(5):467-94. Review.

PMID:
15871634
40.

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.

Courtney R, Sansone A, Smith W, Marbury T, Statkevich P, Martinho M, Laughlin M, Swan S.

J Clin Pharmacol. 2005 Feb;45(2):185-92.

PMID:
15647411
41.

Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil.

Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE, Affrime M, Batra V.

Int J Clin Pharmacol Ther. 2004 Sep;42(9):512-8.

PMID:
15487810
42.

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers.

Reyderman L, Kosoglou T, Boutros T, Seiberling M, Statkevich P.

Curr Med Res Opin. 2004 Sep;20(9):1493-500.

PMID:
15383199
43.

Disposition and pharmacokinetics of temozolomide in rat.

Reyderman L, Statkevich P, Thonoor CM, Patrick J, Batra VK, Wirth M.

Xenobiotica. 2004 May;34(5):487-500.

PMID:
15370964
44.

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.

Kosoglou T, Statkevich P, Fruchart JC, Pember LJ, Reyderman L, Cutler DL, Guillaume M, Maxwell SE, Veltri EP.

Curr Med Res Opin. 2004 Aug;20(8):1197-207.

PMID:
15324522
45.

Pharmacodynamic interaction between ezetimibe and rosuvastatin.

Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL.

Curr Med Res Opin. 2004 Aug;20(8):1185-95.

PMID:
15324521
46.

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.

Kosoglou T, Statkevich P, Meyer I, Cutler DL, Musiol B, Yang B, Zhu Y, Maxwell SE, Veltri EP.

Curr Med Res Opin. 2004 Jun;20(6):955-65.

PMID:
15200755
47.

Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK.

Clin Cancer Res. 2004 May 1;10(9):2968-76.

48.

Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study.

Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD.

Pharmacotherapy. 2004 Jan;24(1):16-25.

PMID:
14740784
49.

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.

Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK.

Br J Cancer. 2003 Apr 7;88(7):1004-11.

50.

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

Awada A, Eskens FA, Piccart M, Cutler DL, van der Gaast A, Bleiberg H, Wanders J, Faber MN, Statkevich P, Fumoleau P, Verweij J; EORTC Early Clinical Studies Group.

Eur J Cancer. 2002 Nov;38(17):2272-8.

PMID:
12441264

Supplemental Content

Loading ...
Support Center